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Abstract
Background: The synovial membrane lines the luminal side of the joint capsule in synovial joints. It maintains joint
homeostasis and plays a crucial role in equine joint pathology. When trauma or inflammation is induced in a joint,
the synovial membrane influences progression of joint damage. Equine synovial membrane research is hampered
by a lack of markers of fibroblast-like synoviocytes (FLS) to distinguish FLS from other fibroblast-like cells in
musculoskeletal connective tissues. The aim of this study is to identify potential FLS markers of the equine synovial
membrane using microarray to compare between gene expression in equine synovial membrane and the joint
capsule in metacarpophalangeal joints.
Results: Microarray analysis of tissues from 6 horses resulted in 1167 up-regulated genes in synovial membrane
compared with joint capsule. Pathway analysis resulted in 241 candidate genes. Of these, 15 genes were selected
for further confirmation as genes potentially expressed by fibroblast-like synoviocytes. Four genes: FOXO1, PXK,
PYCARD and SAMD9L were confirmed in 9 horses by qPCR as differentially expressed in synovial membrane
compared to joint capsule.
Conclusions: In conclusion, FOXO1, PXK, PYCARD and SAMD9L were confirmed as differentially expressed in synovial
membrane compared to joint capsule. These four genes are potential markers of fibroblast-like synoviocytes of the
synovial membrane. As these genes are overexpressed in synovial membrane compared to joint capsule, these
genes could shed light on synovial membrane physiology and its role in joint disease.
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Background
Horses are susceptible to joint disease and trauma leading
to joint pathology. Joint pathology involves complex pro-
cesses, and joint inflammation affects several tissues within
the joint [1]. Regardless which intra-articular tissue type is
first affected, the synovial membrane orchestrates and rein-
forces inflammatory responses of joints [2, 3]. Hence, the
synovial membrane is key to enhance understanding of the
pathophysiological processes within synovial joints.
In the healthy joint, the synovial membrane maintains
joint homeostasis [4]. From its position as luminal lining of
the joint capsule, the synovial membrane facilitates diffu-
sion of plasma ultra-filtrate through synovial extracellular
matrix and produces lubricating synovial additives [4]. Two
cell types constitute the majority of the synovial membrane,
macrophage-like synoviocytes (MLS) and fibroblast-like
synoviocytes (FLS) [5]. MLS are macrophages resident to
the joint [6, 7] which tend to distribute unevenly adjacent
to the joint lumen [8] and to congregate at the top of syn-
ovial villi [6]. From this localisation within the synovial
membrane, the MLS engulf foreign substances [6, 7]. MLS
are characterized by expression of typical general resident
macrophage-markers such as CD11b, CD14, CD68 and
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CD206 [9–11]. The fibroblast-like synoviocytes (FLS) are
modified fibroblasts with cytoplasmatic processes reaching
to the joint lumen. FLS produce and secrete lubricating
additives to the synovial fluid and produce and maintain
the synovial extracellular matrix (ECM). FLS are the
dominating cell-type in the synovial intima (80%) and the
fibroblastic lineage results in characteristic expression of
general fibroblast markers such as vimentin and prolyl
hydroxylase [12]. Due to FLS’s specific functions in the
synovial lining [13], FLS differ from other fibroblasts, but
there are only a few reports of selective markers of FLS
differentiating them from other musculoskeletal fibroblasts.
In humans, the hyaluronan precursor Uridine diphospho-
glucose dehydrogenase (UDPGD) has been proposed as a
specific marker of FLS [14–16]. In mice and humans, the
cell contact mediating protein Cadherin-11, has been sug-
gested as marker of FLS. Cadherin-11 is believed to mediate
synovial lining integrity and to be implicated in synovial
inflammation [3, 17]. None of these molecules have been
investigated in horses and new equine FLS markers in the
synovial membrane could elucidate the normal function of
the synovial membrane and potentially contribute to
unravel mechanisms behind the role of FLS in arthritic
conditions. In addition, novel markers could improve the
consistency and reproducibility of FLS based studies.
Thus, the aim of this study was to identify new markers
of equine healthy FLS in the healthy joint. We compared
the gene expression of the synovial membrane to the gene
expression of the fibrous joint capsule using a microarray
technique. This is a comparison of two tissues each con-
taining different types of fibroblasts, the FLS of the synovial
membrane and fibroblasts from the dense connective tissue
of the joint capsule. This comparison was made to highlight
differences in gene expression between the two types of
cells and thus search out markers not previously explored.
Based on the microarray data we used pathway analysis to
select markers relevant to FLS, and we confirmed the
selected target genes by qPCR to support general
applicability of the markers.
Methods
Microarray experiment
Tissue samples
Synovial membrane and joint capsule tissue samples were
collected from six horses of mixed breed (aged 15–25 years).
The horses were euthanized at the Faculty of Health and
Medical Sciences, University of Copenhagen according to
regulations of Danish law for reasons unrelated to ortho-
paedic disorders in the metacarpophalangeal joints. The
joint capsule was transected and the macroscopic appear-
ance of the joint evaluated. Synovial membrane and joint
capsule were excised from the entire fetlock joint to avoid
site-specific variation within the joint. The synovial mem-
brane was separated from the joint capsule by careful
dissection. This method was verified by embedding
dissected synovial membrane and joint capsule separately
in paraffin and subsequently staining with Mayer’s
Hematoxylin1 and Eosin2 prior to histologic evaluation.
The separated exised tissue from the six horses generated a
yield of 0.6–4.0 g of synovial membrane and joint capsule
from each joint, which was snap frozen in liquid nitrogen.
To evaluate for signs of acute inflammation a full thickness
tissue sample was excised from the proximo-dorsal part of
the joint, fixed in 4% paraformaldehyde3 in PBS,4 and
embedded in paraffin. This sample was later sectioned and
stained with Mayer’s Hematoxylin and Eosin and evaluated
for histologic signs of acute inflammation. The histologic
signs of acute inflammation evaluated were: Cellular infil-
trates in general and in vascular surroundings and/or
hyperplasia of the synovial membrane. Tissues from joints
with macroscopic or cellular signs of inflammation were
excluded from the study.
RNA extraction
For the microarray study, RNA was extracted using Trizol.
Briefly, 1 ml Trizol5 was added to the tissue and the tissue
was homogenised in a Fastprep6 homogeniser for 20 s at
4 m/s. Following 5 min incubation, 0.2 mL of 1-bromo-3-
chloro propane7 was added for phase separation and the
tubes were shaken vigorously by hand for 15 s. Then the
samples were incubated for 2 min, and centrifuged at
12,000 g for 15 min. 500 μL of the aqueous upper phase
was carefully aspirated and transferred to new RNAse free
1.5 mL tubes. The RNA was precipitated by adding 1 μL
of linear polyacrylamide,8 gentle mixing and the addition
of 500 μL isopropyl alcohol.9 Following 10 min incubation
the tubes were centrifuged at 14,000 g for 10 min. The
supernatant was carefully removed and the RNA pellet
washed with 1 mL 75% Ethanol, the tubes inverted and
centrifuged for 5 min at 14,000 g. After a second wash in
75% ethanol the RNA pellet was left to air dry until any
residual liquid had evaporated, approximately 5 to 15 min.
The RNA was re-dissolved in 20 μL of MilliQ water. The
yield of RNA was quantified using a NanoDrop10 spectro-
photometer (Labtech International Ltd., UK) and the
quality assessed using an Agilent RNA 6000 nanochip on
the Agilent Bioanalyser.11
Amplification of the RNA, aminoallyl incorporation and dye
coupling
Total RNA was amplified using the MessageAmp™ II aRNA
Amplification Kit,12 and spiked control RNA’s were added
according to the Agilent Spike in Kit13 with 500 ng RNA
and 5 μl Spike mix added to each well and the volume
adjusted to 10 μl by adding nuclease-free water.
Reverse transcription of RNA was initiated by adding
10 μl of a reverse transcription mastermix containing
reverse transcriptase, NTP and T7 Olio d(T) primer and
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incubated according to the manufacturer’s instructions.
After 2 h at 42 °C the temperature was dropped to 16 o
C and second strand synthesis started using a mixture of
fresh NTP with DNAse and Ribonuclease H and incu-
bated for a further 2 h. Double stranded cDNA was
purified on a spin column before aRNA synthesis.
The aRNA was synthesized by in vitro transcription. In
vitro transcription was performed by adding 16 μl cDNA
to a mixture consisting of 3 μl 5-(3-aminoallyl)-UTP,14
4 μl T7 ATP solution, 4 μl T7 CTP solution, 4 μl T7 GTP
solution, 2 μl T7 UTP solution, 4 μl T7 10 Reaction Buffer
and 4 μl Enzyme mix, according to manufacturer’s
instructions. The aRNA was purified according to the
MessageAmp™ II aRNA Amplification Kit protocol. The
yield of the aRNA was assessed using a NanoDrop. The
uniformity of the size of the aRNA was assessed using a
RNA 6000 nanochip on the Agilent Bioanalyser.
Cy315 dye was coupled to aminoallyl UTP (aaUTP) in
the amplified aRNA, according to manufacturer’s in-
structions. The yield and specific activity of the eluate
containing the purified labelling reactions was quantified
using a Nanodrop TM Spectrophotometer (Labtech
International Ltd., UK).
Fragmentation and hybridisation of the samples to the
Agilent Array
Twelve Agilent equine microarrays were used in the
study. Each microarray was hybridised with a single la-
belled RNA sample. The Cy 3 labelled aRNA (10 μl) was
mixed with 10 μl blocking Agent, 31.8 μl nuclease free
water, and 2.2 μl fragmentation buffer,16 and incubated
at 60 °C for 30 min. The reaction was stopped by adding
GE hybridization buffer. The samples were loaded onto
the array and the sides were placed in rotisserie in a
hybridization oven at 65 °C for 17 h.
Scanning of array and subsequent data analysis
After hybridization, the arrays were scanned on a 4200A
axon scanner17 using autoPMTand the appropriate GAL file.
Image files were imported using Agilent Feature ex-
traction software18 and Grids were manually fitted to the
arrays according to the manual. The extracted intensities
were imported into Partek Genomics Suite19 where they
were analysed using the gene expression workflow. The
array data was normalised using a quantile normalisation
where the software calculates the distribution model
from the data files and normalize the probes according
to the calculated distribution model. Analysis of variance
was performed on the normalized data, with Bonferroni’s
correction applied.
The Agilent equine microarray was not fully anno-
tated, but the annotation was improved by importing
ENS numbers and LOC numbers from AgBase [18, 19].
A list of the accession numbers for each non-annotated
probe was prepared and used to query the AgBase data-
base using the online search tool.
The significantly up-regulated genes were imported
into IPA [20]. Significantly overexpressed canonical
pathways were explored.
Confimation of microarray data
Tissue samples
The microarray results were confirmed using qPCR on
synovial membrane and joint capsule in nine horses
(three of the horses from the microarray experiment and
six additional horses of mixed breed (aged 2–22 years)).
Equine synovial membrane and joint capsule was excised
and processed as described previously, and presence of
joint pathology was evaluated as previously described.
RNA extraction
RNA from the tissue samples was extracted using the
Promega SV total RNA Isolation system,20 according to
manufacturer’s instructions.
The yield of RNA was measured using a NanoDrop
TM Spectrophotometer21 and the quality assessed by
using an Agilent Bioanalyser.22
Subsequently, the RNA was transcribed to cDNA by
adding 5× MMLV RT buffer,23 dNTP24 (10 nM), random
hexamer primer25 (2 μg/μL), oligo(dt)26 (0.5 μg/μL), RNasin
RNase inhibitor27 (40 U/μL) and MMLV reverse transcript-
ase enzyme28 (200 U/ μL) to 800 ng RNA diluted in H2O
to a 25 μL reaction volume. The cDNA was transcribed at
25 °C for 10 min, 42 °C for 60 min, 95o C for 5 min. The
cDNA was stored at −20 o C and subsequently diluted to a
concentration of 4 ng/μL for all samples.
Selection of reference genes
The following reference genes were tested for qPCR: 18S
ribosomal RNA (18 S), glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), β-actin, mitochondrial ribosomal
protein S7 (MRPS7), and 5-aminoimidazole-4-carboxa-
mide ribonucleotide formyltransferase /IMP cyclohydro-
lase (ATIC). 18S was chosen as reference gene.
Primer design, candidate genes
The equine gene sequences corresponding to the 15 se-
lected candidate genes were found in Ensembl [21]. If
multiple transcript variants existed, primers were designed
in conserved sequences. The transcript sequences (mRNA
sequences) were inserted in the programme Primer 3 [22].
The chosen primer sequences were subsequently screened
against the horse genome using BLAST ref. [23] to ensure
primer specificity. Amplified gene products were con-
firmed for specificity through sequencing. Only primer
sets with amplification efficiency between 1.8–2.2 were
used. Primer sequences are listed in Table 1.
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qPCR
The quantitative real time polymerase chain reaction
(qPCR) was performed in 96 wells plates on Lightcycler
480 using SYBR Green I29 detection. Each reaction con-
sisted of 10 μl containing 2 μl cDNA, 1 μl forward primer,
1 μl reverse primer, 5 μl master mix and 1 μl H2O. All sam-
ples were tested for genomic contamination by the use of
an intron-spanning primer set unrelated to the study.
Gene expression of the target genes was calibrated be-
tween qPCR runs, and all samples were run in triplicate.
The relative gene expression was calculated using Pfaffl’s
methods [24, 25] and normalised to the reference gene
18S. The relative normalised gene expression was ana-
lysed between synovial membrane and joint capsule.
Mean normalised gene expression was analysed using
Student’s t test in SAS JMP software.30 The assumption
of normal distribution was not met, but the assumption
of equal variances was met for 10 of 15 groups (Table 2).
Results
Microarray analysis
The microarray analysis of variance resulted in 2995
probes from 1907 genes significantly differentially
expressed in synovial membrane compared to joint cap-
sule (p ≤ 0.05). Selection of the genes up-regulated in
synovial membrane rendered 1167 genes.
Ingenuity Pathway Analysis (IPA) [20] was used to select
relevant up-regulated genes in synovial membrane as
potential FLS candidate genes. The top biological functions
explored were: ‘Connective tissue disorders’, ‘Inflammatory
disease’ and ‘Skeletal and Muscular disorders’. Within
‘Connective tissue disorder’, the functions annotations of
rheumatic disease, arthritis, and rheumatoid arthritis were
analysed. In addition, we explored the molecular and cellu-
lar function categories: ‘Tissue morphology’, ‘Small molecule
biochemistry’, ‘Cell morphology’, and ‘Cellular movement’.
A total of 241 genes were evaluated as potential candi-
date genes. Genes were included in the final candidate
gene-list if they related to FLS function or cellular origin
Table 1 Primers used to confirm the expression of candidate genes found in microarray experiment
Target Accession Forward primer Reverse primer Product size (base-pair)
ATXN1 [Genbank: XM_001496252] CCCAAAAGCGAGAACTTCAG TCCGTTTTCAAGTCCTCCAC 206
COL11A1 [Genbank: XM_001918115] GGCAATTCCATTAACATGGTG TTGATCCCAGGAATCGAAGT 151
COL28A1 [Genbank: XM_001494969] AGACTCCGCTAGAGCTGCTG AAGTCGTCCTTGCTGGAGAA 202
FSTL1 [Genbank: XM_001500510] ACAAGAGGCCTGTGTGTGG TGTCCGTCATAATCGACCTG 130
FOXO1 [Genbank: XM_005601179] CCAGCCCAAACTACCAAAAA AACACATTCTGGCCAAGGAC 241
GALNT3 [Genbank: XM_001496049] CCTTGCTCTGTTGTTGGACA TGCTGCATCTGTGTTTCTCC 153
GRN [Genbank: XM_001489741] TGTGAGGAGGGACTGAGGAC TTGTTACGTGGCTTTCACCA 207
ITPR3 [Genbank: XM_005604053] GCAGTTTGGGATGATGCAGT CTGGGCTCTCGGTTCTTG 159
NF1 [Genbank: XM_005597955] TGGCCCTGTACATGTTTCTG TTGCTGACAGACGCAAATTC 172
PXK [Genbank: XM_008519676] CATTACCTCCACCTCCTCCA GATCACAGGTTTCGGCTTTC 180
PYCARD [Genbank: XM_001500509] CCATCCTAGAGGCACTGGAA CTCCGTACGCCTCCAGATAG 177
RGL2 [Genbank: XM_001497200] GGATGGAGCTTCACACGATT CAGGATGGCTACCCACATCT 235
SAMD9L [Genbank: XM_005609186] GAACCGGAAAACGTCTGTGT GGGAGAAAGTCGGTGCATTA 171
SOS1 [Genbank: XM_005600032] CACGAGAACCTGTGAGGACA AAGTGCTTTGTCGAGGAGGA 249
TIMP3 [Genbank:NM_001081870] CCTGCTACTACCTGCCTTGC GGTCTGTGGCATTGATGATG 186
Table 2 Real-time polymerase chain reaction results for the
15 selected candidate genes
Target gene Synovial membrane Joint capsule
ATXN1 0.40 ± 0.30b 0.43 ± 0.30
COL11A1 1.35 ± 1.81 0.43 ± 0.47
COL28A1 0.36 ± 0.47b 0.17 ± 0.28
FSTL1 7.75 ± 9.99a 0.27 ± 0.32
FOXO1 3.35 ± 2.97* 0.93 ± 1.15
GALNT3 0.99 ± 1.70 0.15 ± 0.17
GRN 7.05 ± 7.63a 1.44 ± 1.66
ITPR3 1.90 ± 1.11b 1.07 ± 0.83
NF1 2.96 ± 3.42 5.60 ± 5.96
PXK 7.49 ± 7.69* 0.49 ± 0.62
PYCARD 2.70 ± 2.43* 0.34 ± 0,29
RGL2A 2.06 ± 1.70b 1.37 ± 1,66
SAMD9L 5.39 ± 4.79* 0.45 ± 0.45
SOS1 1.83 ± 2.19b 0.77 ± 0.77
TIMP3 32.26 ± 46.34a 2.95 ± 4.06
Results are reported as expression of target gene relative to expression of 18S,
the expression is furthermore normalised to a calibrator. The reported results
are mean expression ± standard deviation. Difference between groups was
tested with a Student’s t-test. *Significant difference between Synovial
membrane and Joint capsule, p ≤ 0.05. aDifferential expression in synovial
membrane compared to joint capsule p value ≤0.10. bTest of equal variances
in the groups was not significant
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(mesenchymal cells). This led to a sub-classification of
the genes into the following groups: genes potentially re-
lating to FLS function, genes potentially relating to FLS
cell morphology, genes relating to mesenchymal cells, or
adverse genes (genes relevant to diseases involving mes-
enchymal cells).
This led to selection of 15 candidate genes. The fold
change and the p-values of the 15 candidate genes in the
microarray study are presented in Table 3.
Real-time PCR confirmation of candidate genes
The relative quantification analysis detected significantly
different gene expression of FOXO1, PXK, PYCARD and
SAMD9L at significance level p ≤ 0.05 between synovial
membrane and joint capsule (Table 2). In addition, the
genes FSTL1, GRN and TIMP3 were expressed differ-
ently in synovial membrane compared to joint capsule at
significance level p ≤ 0.10 (Table 2).
Discussion
In this microarray study, we investigated new markers of
the equine synovial membrane by comparing gene ex-
pression of synovial membrane to the gene expression of
the joint capsule. Of 1167 genes up-regulated in the syn-
ovial membrane, we evaluated 241 genes with potential
relevance to FLS to search for FLS markers. Genes were
included in the final candidate gene-list, if the genes
could be related to mesenchymal origin or FLS function.
By careful selection of relevant candidate genes, the final
candidate gene-list was reduced to 15 genes.
We reduced variations in probe set expression and gene
expression between horses by normalisation between mi-
croarrays. Barrey et al., 2009 used data mining software to
identify networks and associated genes in an equine micro-
array study [26]. In the present study relevant networks
were visualised using Ingenuity Pathway Analysis (IPA),
and the filtering process applied related to IPA results and
a subjective selection of putative candidate genes. The sub-
jective filtering process involved exclusion of genes with
known expression in macrophages, endothelial cells or neu-
rons, and genes with known ubiquitous gene expression.
Genes with known mesenchymal expression were included
in the candidate gene-list, even though this could include
genes simultaneously expressed in adipocytes, connective
tissue fibroblasts, chondrocytes and osteoblasts. This filter-
ing process is likely to have excluded some potential novel
markers of FLS, and it is highly relevant to further explore
the gene list of up-regulated genes in synovial membrane.
Inter-horse variation and anatomical location may affect
the results. Huang et al., 2008 compared ten different types
of tissue to cartilage to identify novel markers of cartilage.
Most of the samples in the study by Huang et al., 2008 were
taken from the same horse [27]. Rinn et al., 2006 showed
different gene expression in fibroblasts from various ana-
tomical locations [28]. We aimed to minimize anatomical
variation by excising samples from only one joint in a total
of 12 horses. However, our candidate gene list may include
genes differentially expressed merely as a result of the
anatomical position of the cells instead of being specific to
synovial membrane fibroblast-like cells.
Table 3 Microarray Fold change and p-values for the 15 selected candidate genes
Gene symbol Function Fold change p-value ANOVA
ATXN1 Embryonal ECM remodelling 2.48 2.96E-03
COL11A1 Collagen in ECM 11.82 2.93E-04
COL28A1 Collagen in vascular ECM 21.29 1.63E-04
FSTL1 Unknown, embryonal mesenchymal location 4.10 2.59E-03
FOXO1 Transcription factor, function in osteoblast homeostasis 2.33 2,50E-05
GALNT3 Glycosylation, golgi complex 5.65 8.88E-07
GRN Regulate cell growth 1.99 5.49E-06
ITPR3 Second messenger, possible role in exocrine secretion 3.09 6.64E-04
NF1 Regulate cell growth 3.27 4.35E-04
PXK A functionel sorting nexin 4.81 1.72E-04
PYCARD Function in inflammasomes 3.70 8.63E-05
RGL2A Protein transport in cells 1.58 1.64E-05
SAMD9L Protein-protein interaction 4.88 5.80E-04
SOS1 Promotes reorganization of actin cytoskeleton 2.90 1.20E-03
TIMP3 Metalloproteinase inhibitor 1.75 9.79E-04
ATXN1 ataxin 1, COL11A1 collagen XI α1, COL28A1 collagen XXVIII α1, FOXO1 forkhead box O1, FSTL1 follistatin-like 1, GALNT3 UDP-N-acetyl-alpha-D-galactosamine:-
polypeptide N-acetylgalactosaminyltransferase 3 (GalNac-T3), GRN granulin, ITPR3 inositol 1,4,5-trisphosphate receptor, type 3, NF1 neurofibromin 1, PXK PX
domain containing serine/threonine kinase, PYCARD PYD and CARD domain containing, RGL2 RGL2, ral guanine nucleotide dissociation stimulator-like 2, SAMD9L
sterile alpha motif domain containing 9-like, SOS1 son of sevenless homolog 1 (Drosophila), TIMP3 TIMP metallopeptidase inhibitor 3
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It has also been shown that age, gender, breed, and ac-
tivity level can contribute to variation in levels of bio-
markers in the joint or serum in horses with osteoarthritis
[29–31]. In our study, we included mixed breed, gender,
and age searching for candidate genes of general applic-
ability. It was not the aim of this study to investigate the
influence of breed, gender or age on the gene expression
of the synovial membrane compared to the joint capsule
which would call for a larger sample size.
The differential gene expression of FOXO1, PXK,
PYCARD and SAMD9L was confirmed using qPCR. In
addition, the genes: FSTL1, GRN and TIMP3 showed a
tendency towards higher gene expression in synovial
membrane compared to joint capsule.
The genes presented here represent possible new
markers of the synovial membrane. Knowledge of func-
tion of the four significantly differentially expressed
genes in horses is limited. But in humans, the forkhead
transcription factor FOXO1 has turned out to be a regu-
lator of glucose expenditure in cells and plays a role in
regulation of glucose homeostasis in osteoblasts [32].
This suggests that FOXO1 may regulate glucose homeo-
stasis in FLS. Human FOXO1 is also expressed in acti-
vated macrophages in lung tissue [33]. It could therefore
be expressed in activated macrophages in joints, but a
study in human rheumatoid arthritis synovial membrane
showed that FOXO1 expression occur mainly in FLS and
only occasionally in MLS, supporting the use of FOXO1
as a marker of FLS [34].
PXK encodes a phox homology domain, which is sug-
gested as a sorting nexin localised in endosomes in cells
and possibly interacting with actin. These functions sug-
gest that PXK is involved in sorting processes in the cells
and possibly in receptor trafficking [35].
PYCARD encodes for a protein in inflammasomes, a
multiprotein complex which contributes to initiating the
inflammatory process by activation of pro-caspase 1,
which further leads to production of inflammatory cyto-
kines [36]. Evidence indicates that the protein encoded
by PYCARD is expressed in both FLS and MLS [37], but
not at a high level in joint capsule fibroblasts according
to the present study. Further studies are warranted to
clarify if the expression of PYCARD is found in both
FLS and MLS of the synovial membrane.
Expression of the gene SAMD9L has been located to a
variety of tissues, but the exact function of the gene
transcript is unknown. A recent study has investigated
proliferation depressing effects of SAMD9L, and
SAMD9L expression was reduced in tumours [38]. Thus,
if SAMD9L is specifically expressed by FLS in synovial
membrane and the gene has a proliferation depressing
effect, the expression of the gene in FLS from joints with
inflammatory arthritis or rheumatoid arthritis should be
investigated. It is worth noting that neither of the human
FLS markers suggested in the literature, UDPGD nor
cadherin 11, appeared on the list of significantly up-
regulated genes in our microarray study.
Conclusions
In conclusion, the genes FOXO1, PXK, PYCARD and
SAMD9L were confirmed as differentially expressed be-
tween synovial membrane and joint capsule. We suggest
inclusion of the genes FOXO1, PXK, PYCARD and
SAMD9L as potential markers of FLS in future studies
of the equine synovial membrane.
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